{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-065598","form_type":"8-K","ticker":"FOXO","cik":"0001812360","company_name":"FOXO TECHNOLOGIES INC.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.365688+00:00","generated_at":"2026-06-11T18:45:29.665662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"FOXO narrows Q2 loss to $0.49 EPS; capital structure streamlined, raises ~$260K in private placement","bullets":["Basic EPS loss of $0.49 in Q2 2023 vs $3.84 loss a year ago; diluted loss $0.83 vs $6.01.","Adjusted EBITDA loss improved to $3.34M in Q2 from $8.82M in prior-year quarter; six-month loss $7.20M.","Completed two tender offers: 1.65M warrants exchanged for 7.96M shares; 4.32M shares issued to PIK note holders.","Raised ~$260K net proceeds from private placement of 5.625M shares of Class A common stock.","Launched Bioinformatics Services in July 2023; paused Longevity Report beta sales for further R&D."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-065598","json":"https://secwatch.observer/filing/0001213900-23-065598.json","markdown":"https://secwatch.observer/filing/0001213900-23-065598.md","text":"https://secwatch.observer/filing/0001213900-23-065598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812360/000121390023065598/0001213900-23-065598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812360/000121390023065598/ea183281-8k_foxotech.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:45:29.665662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7458af800a932e5244c2b7493ce3eb824464037f","claim":"FOXO TECHNOLOGIES INC. reported second quarter ended June 30, 2023 results: EPS $(0.49) and $(0.83) for the three and six months ended June 30, 2023, respectively from $(3.84) and $(6.01) for the thre.","evidence_excerpt":"FOXO Technologies Inc. (NYSEAM: FOXO), a leader in the field of commercializing epigenetic biomarker technology, today reported financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1812360/000121390023065598/0001213900-23-065598-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"EPS","value":"$(0.49) and $(0.83) for the three and six months ended June 30, 2023, respectively from $(3.84) and $(6.01) for the thre"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}